Intest Res.  2018 Apr;16(2):319-320. 10.5217/ir.2018.16.2.319.

The old versus the new: which do you keep in postoperative Crohn's disease?

• Kotze PG
• Ma C
• Regueiro M
• Panaccione R

• KMID: 2417687
• DOI: http://doi.org/10.5217/ir.2018.16.2.319

Abstract

No abstract available.

MeSH Terms

Crohn Disease*

Reference

1. Hiraoka S, Takashima S, Kondo Y, et al. Efficacy of restarting anti-tumor necrosis factor alpha agents after surgery in patients with Crohn's disease. Intest Res. 2018; 16:75–82. PMID: 29422801.

2. Kotze PG, Yamamoto T, Damião AO. Postoperative approach for Crohn's disease: the right therapy to the right patient. Curr Drug Targets. DOI: 10.2174/1389450116666151102094922. [published online ahead of pirnt November 1, 2015].

3. De Cruz P, Kamm MA, Hamilton AL, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet. 2015; 385:1406–1417. PMID: 25542620.

4. Regueiro M, Feagan BG, Zou B, et al. Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection. Gastroenterology. 2016; 150:1568–1578. PMID: 26946343.

5. Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016; 7:289–300. PMID: 28839870.